Your session is about to expire
← Back to Search
CB-839 + Panitumumab + Irinotecan for Colorectal Cancer
Study Summary
This trial is testing glutaminase inhibitor CB-839 with panitumumab and irinotecan hydrochloride to treat patients with colorectal cancer that has spread and does not respond to treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My kidney function is normal or only slightly impaired.I am fully active or restricted in physically strenuous activity but can do light work.I've had chemotherapy for advanced disease or worsened within 6 months after adjuvant therapy.I haven't had any cancer treatment in the last 28 days.I cannot take medicine by mouth.I haven't had cancer, except for certain skin, cervical, or ductal cancers, in the last 5 years.I am not pregnant, will use 2 birth control methods, and am not menopausal unless confirmed by a test.I am a man who can father children and agree to use two forms of birth control until 2 months after my last treatment dose.I do not have any active infections, or if I do, they have been under control with antibiotics for at least 14 days.I have an active bowel condition causing chronic diarrhea or obstruction.My brain metastasis is stable, treated, or without symptoms for at least 30 days.I've had anti-EGFR therapy before and my cancer didn't worsen after treatment.I agree to have a biopsy and four PET scans for research before and after my first treatment cycle.I experienced severe side effects from irinotecan treatment.I have or had lung scarring or inflammation.My colorectal cancer is confirmed to be KRAS wildtype and has spread.I haven't had major surgery with general anesthesia in the last 28 days.I have Gilbert's disease.I have a tumor that can be measured and monitored with scans.
- Group 1: Panitumumab/Irinotecan/CB-839
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What therapeutic applications is Glutaminase Inhibitor CB-839 employed for?
"Colorectal carcinoma sufferers often benefit from Glutaminase Inhibitor CB-839. This medication is also effective in treating ovarian cancer, sarcoma, and metastatic colorectal carcinoma."
What are the principal goals of this exploration?
"Calithera Biosciences, Inc - the study sponsor- has specified that Maximum tolerated dose (Phase I) B-839 in combination with panitumumab and irinotecan hydrochloride will be tracked as a primary outcome over a period of 12 months. Further, secondary outcomes such as Maximum Standardized Uptake Value (SUVmax) of fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG), Disease control rate, and Progression free survival (phase II) will all be assessed. The latter two metrics entail quantifying the"
What is the participant quota for this research endeavor?
"Affirmative. Information published on clinicaltrials.gov confirms that registration is open for this medical research, which was initially posted in August 2017 and updated at the end of November 2022. A total of 40 participants are being sought from a single site."
Are there any vacant positions available for participants in this experiment?
"According to the data sourced from clinicaltrials.gov, this investigation is currently recruiting participants that meet its eligibility criteria. The trial was first published on August 23rd 2017 and has since been updated most recently on November 22nd 2022."
Could you please summarize previous investigations into Glutaminase Inhibitor CB-839?
"At present, there are 54 Phase 3 and 288 open trials studying Glutaminase Inhibitor CB-839. Indeed, a total of 8933 medical facilities worldwide have conducted studies on this inhibitor with the majority located in Woolloongabba, Queensland."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger